Alperen Taş | Cardiology | Best Researcher Award

Published on by Academic Awards

Dr. Alperen Taş | Cardiology | Best Researcher Award

Ahi Evran University | Turkey

Dr. Alperen Taş is an emerging cardiology researcher whose work centers on acute heart failure, coronary syndromes, inflammatory biomarkers, prognostic scoring systems, and no-reflow phenomena. He focuses on developing and validating clinical biomarkers and risk-prediction models that enhance early diagnosis, guide clinical decisions, and improve mortality prediction in high-risk cardiac patients. His peer-reviewed contributions span key diagnostic tools, including the Scottish Inflammatory Prognostic Score, prognostic nutritional index, QT interval–GRACE score integration, intracoronary ECG, HALP score, Osaka Prognostic Score, and novel biomarkers such as PDGF-BB, chemerin, and derived NLR. His collaborative studies explore infective endocarditis, myocardial infarction, coronary no-reflow, heart failure progression, echocardiographic functional assessment, and medication-related cardiovascular effects. He has shared his findings at national cardiology congresses, advancing scientific dialogue on inflammatory markers and cardiovascular prognostication. With 12 publications, 24 citations, and an h-index of 2, Dr. Alperen Taş demonstrates solid developing research impact, strong collaboration, and a promising trajectory in preventive cardiology and biomarker-based risk stratification.

Profile: Scopus

Featured Publications

Taş, A., Tunca, Ç., Tanık, V. O., & Özlek, B. (2025). The Scottish inflammatory prognostic score: A novel biomarker for predicting in-hospital mortality in acute heart failure with reduced ejection fraction. Heart & Lung, 74, 291–299.

Mehmet Arif İçer | Cardiology | Best Researcher Award

Published on by Academic Awards

Assist. Prof. Dr. Mehmet Arif İçer | Cardiology | Best Researcher Award

Assist. Prof. Dr. Mehmet Arif İçer, Amasya University, Turkey

Assist. Prof. Dr. Mehmet Arif İçer is a dedicated academic at the Department of Nutrition and Dietetics, Amasya University, Turkey. With a PhD from Gazi University 🎓, he has authored over 28 impactful research articles in top journals, achieving 980+ citations and an h-index of 11. His work focuses on clinical nutrition, dietary biomarkers, and metabolic health. He was named among Stanford’s Top 2% Scientists in 2024. He also serves as Head of Department and Vice Dean at Amasya University, reflecting his academic leadership. He is passionate about evidence-based nutrition and public health

Publication Profile

Google Scholar

🎓 Educational Background

Assist. Prof. Dr. Mehmet Arif İçer pursued his academic journey in Nutrition and Dietetics with distinction. He earned his PhD (2018–2022) and MSc (2016–2018) from Gazi University in Ankara, Turkey . He completed his BSc at Erciyes University, Kayseri (2009–2014), where he laid the foundation for his expertise in clinical nutrition and dietetics . Enhancing his global perspective, he participated in the Erasmus program at Semmelweis University, Budapest , during 2014. His strong academic background reflects a commitment to excellence and innovation in nutritional science and public health education

Professional Experience

Dr. Mehmet Arif İçer began his academic career as a Research Assistant at Amasya University (2014–2015) 🏫, later continuing at Gazi University from 2015 to 2022 🧪. In 2022, he returned to Amasya University as an Assistant Professor 👨‍🔬. His leadership capabilities led to appointments as the Head of the Department of Nutrition and Dietetics and Vice Dean of the Faculty of Health Sciences in 2023. Dr. İçer’s career reflects a strong dedication to research, academic development, and administrative excellence within the fields of nutrition and public health sciences

🔬 Research Focus

Dr. Mehmet Arif İçer’s research primarily explores the intersection of clinical nutrition, biochemistry, and chronic disease prevention. His studies focus on biomarkers like fetuin-A and osteopontin in metabolic and cardiovascular disorders . He also investigates orthorexia nervosa, kidney stones, and gut-brain axis interactions, particularly through the roles of dietary lipids, microbiota, and lactic acid bacteria 🧬🥦. His multidisciplinary approach bridges nutritional genomics, dietary behavior, and public health 🩺📊. With a strong emphasis on evidence-based dietary strategies, Dr. İçer contributes to advancing preventive health through innovative nutrition science and functional food research

Publication Top Notes

📘 The multiple functions and mechanisms of osteopontin – 653 citations 📈 (2018) 🧬
📘 Effects of fetuin-A with diverse functions and multiple mechanisms on human health – 62 citations 📊 (2021) 🧠
📘 The roles of dietary lipids and lipidomics in gut-brain axis in type 2 diabetes mellitus – 52 citations 🔬 (2023) 🥑🧠
📘 Effects of vitamin E on neurodegenerative diseases: An update – 42 citations 🧠 (2021) 🍊
📘 The impacts of acidophilic lactic acid bacteria on food and human health – 39 citations 🧪 (2023) 🥛
📘 Urine osteopontin levels in nephrolithiasis diagnosis – 28 citations 🧫 (2018) 🧂
📘 Effects of nutritional status on serum fetuin-A level – 25 citations 🧍‍♂️ (2020) 🧪
📘 GABA by lactic acid bacteria & human health – 17 citations 🧠 (2024) 🥬
📘 Pharmacological effects of licorice on human health – 16 citations 🌿 (2017) ⚕️
📘 Healthy food/activity choices & body weight in preschool children – 13 citations 🧒 (2017) 🥗
📘 Effects of red pepper, ginger, turmeric on energy metabolism – 11 citations 🌶️ (2021) 🔥
📘 Dietary intake & kidney stone formation risk – 9 citations 🥤 (2019) 💎
📘 PRAL level in nephrolithiasis patients & nutritional status – 5 citations 🧂 (2018) 🧪
📘 Coffee’s cardiometabolic potential & health relationships – 4 citations ☕ (2024) ❤️

Vahid Eslami | Cardiology | Best Researcher Award

Published on by Academic Awards

Assoc. Prof. Dr. Vahid Eslami | Cardiology | Best Researcher Award

Assoc. Prof. Dr. Vahid Eslami, Shahid Modarres hospital, Iran

Assoc. Prof. Dr. Vahid Eslami is a board-certified Interventional Cardiologist and Structural Heart Specialist based in Tehran, Iran. With over 14 years of experience, he specializes in high-risk coronary interventions, TAVI, CTO angioplasty, and advanced cardiac imaging (IVUS, OCT). 🏥 As Head of the Cardiovascular Department at Shahid Beheshti University, he leads clinical education and research, boasting 50+ peer-reviewed publications and an H-index of 11. 🎓 A Fellow of the American College of Cardiology and member of ESC, EAPCI, and ISOIC, Dr. Eslami actively mentors cardiology trainees and presents at global cardiology congresses.

Publication Profile

Google Scholar

Professional Experience

Assoc. Prof. Dr. Vahid Eslami is a distinguished Interventional Cardiologist and Head of the Cardiovascular Department at Shahid Beheshti Medical University, Tehran. With over a decade of clinical and academic excellence, he has led multidisciplinary teams, performed over 500 complex coronary interventions, and implemented advanced imaging technologies like IVUS and OCT. 📈 He has overseen impactful research, contributing to 20+ high-impact publications and international conference presentations. 🏥 As a medical educator, he has trained over 100 cardiology residents and fellows. 🧑‍⚕️ A respected leader and national board member for myocardial infarction treatment, he actively shapes Iran’s cardiovascular protocols. 🌍

🎓 Education & Medical Training

Dr. Vahid Eslami completed his Doctor of Medicine (MD) at Tehran University of Medical Sciences (1999–2006), ranking 11th among 300,000 applicants in the national entrance exam. 🏅 He pursued a Cardiology Residency (2006–2010) at Shahid Beheshti University of Medical Sciences, where his thesis on QT dispersion post-primary PCI was published in a U.S. journal. 🫀 He then completed a Fellowship in Interventional Cardiology (2012–2014) at the same university, focusing on coronary angiography and FFR, with his research again featured in international journals. 📘 His training solidified his expertise in advanced cardiovascular care and research

🏅 Licenses & Certifications

Dr. Vahid Eslami is a board-certified Interventional Cardiologist, accredited by the American College of Cardiology (ACC) 🎓. He holds active memberships in several esteemed cardiology organizations, including the American College of Cardiology , the European Association of Percutaneous Cardiovascular Interventions (EAPCI) , and the Iranian Society of Interventional Cardiology (ISOIC) . These affiliations reflect his global engagement and adherence to the highest standards of cardiovascular care.His certifications and memberships support his ongoing contributions to research, education, and innovation in interventional cardiology.

🧠🔬 Research Focus

Assoc. Prof. Dr. Vahid Eslami’s research is deeply rooted in interventional cardiology, with significant contributions to COVID-19 cardiovascular outcomes , anticoagulation therapies, and ischemic heart disease. His studies focus on complex coronary interventions, QT interval dynamics, inflammatory biomarkers, and gender differences in cardiac risk. He’s actively involved in randomized controlled trials and has examined the visual-functional mismatch in coronary diagnostics. He also explores the role of epicardial fat and cardiac imaging indices in disease progression. His multidisciplinary work bridges clinical practice and cardiovascular research, advancing protocols for acute and critical care cardiology

Publication Top Notes

  • 📄 Effect of intermediate-dose vs standard-dose prophylactic anticoagulation… – 📊738 citations | 📅2021

  • 📄 Intermediate-dose versus standard-dose prophylactic anticoagulation in patients with COVID-19… – 📊87 citations | 📅2022

  • 📄 Atorvastatin versus placebo in patients with covid-19 in intensive care… – 📊76 citations | 📅2022

  • 📄 Evaluation of QT, QT dispersion, and T-wave peak to end time changes… – 📊61 citations | 📅2013

  • 📄 Association of CT-measured cardiac indices with lung involvement in COVID-19 – 📊48 citations | 📅2021

  • 📄 Are women more susceptible to ischemic heart disease? A literature overview – 📊36 citations | 📅2021

  • 📄 Epicardial adipose tissue, inflammatory biomarkers and COVID-19 – 📊31 citations | 📅2021

  • 📄 Extrinsic compression of left main coronary artery by the pulmonary trunk… – 📊28 citations | 📅2009

  • 📄 Management of STEMI during COVID-19: Iranian “247” National Committee’s position paper – 📊26 citations | 📅2021

  • 📄 Prognostic value of inflammatory biomarkers in COVID-19 patients – 📊15 citations | 📅2021

Shixun Wang | Cardiology | Best Researcher Award

Published on by Academic Awards

Dr. Shixun Wang | Cardiology | Best Researcher Award

Professor at Weifang People’s Hospital, China

Dr. Wang Shixun 👨‍⚕️, born in October 1979, is a distinguished cardiovascular specialist at Weifang People’s Hospital. He earned his doctorate in Cardiovascular Medicine from Weifang Medical College in 2006 and has over 18 years of clinical experience. Currently serving as Deputy Director, he is applying for the position of Chief Physician 👨‍🔬. Known for his excellence in clinical practice, he received top evaluation ratings from 2018 to 2021 🌟. Dr. Wang demonstrates strong computer and foreign language skills 💻🗣️ and is highly respected for his dedication to cardiovascular care and hospital leadership ❤️🏥.

Publication Profile

Scopus

Orcid

Academic Background

Dr. Wang Shixun 👨‍⚕️ graduated from Weifang Medical College in July 2006 🎓, earning his doctorate in Cardiovascular Medicine ❤️. Immediately after graduation, he began his medical career at Weifang People’s Hospital 🏥, demonstrating a seamless transition from academic training to clinical practice. With a strong foundation in medical education and a passion for patient care 💉, Dr. Wang quickly established himself as a dedicated healthcare professional. His long-term commitment to the same institution reflects both loyalty and deep institutional knowledge 📘, making him a valuable asset to the hospital and the broader medical community 🌟.

Professional Experience

Dr. Wang Shixun 👨‍⚕️ obtained his current professional and technical qualifications in March 2017 and has since shown remarkable growth in the field of Cardiovascular Medicine ❤️. He was first appointed to his current role in September 2018 and has accumulated five years of dedicated service in this position. Dr. Wang now applies for the title of Chief Physician, reflecting his advanced clinical expertise and leadership readiness 🧠. He also serves as Deputy Director 🏥, balancing administrative responsibilities with medical duties. Additionally, he has demonstrated proficiency in computer applications 💻, enhancing his effectiveness in modern healthcare delivery.

Awards and Honors

Dr. Wang Shixun 👨‍⚕️ has consistently demonstrated excellence in his medical career, earning outstanding performance evaluations for four consecutive years—2018, 2019, 2020, and 2021 🏅. These “Excellent” ratings reflect his dedication, clinical skill, and strong work ethic in the field of Cardiovascular Medicine ❤️. In 2022, he continued to maintain a high standard with a “Qualified” rating ✅. His consistent recognition by peers and superiors underscores his commitment to medical excellence and patient care 🙌. These honors highlight Dr. Wang’s growing influence and leadership within the hospital and the broader medical community 🏥✨.

Research Focus

Dr. Wang Shixun 👨‍⚕️ is deeply engaged in the field of Cardiovascular Medicine, with a strong focus on clinical research aimed at improving patient outcomes and advancing treatment strategies for heart-related conditions ❤️🫀. His work emphasizes evidence-based practices, integrating the latest medical advancements into routine care 🧬📊. As Deputy Director at Weifang People’s Hospital 🏥, he actively participates in research initiatives and fosters a collaborative environment for innovation and knowledge sharing 🤝💡. With his solid academic foundation and practical experience, Dr. Wang continues to explore new frontiers in cardiovascular healthcare to benefit patients and the medical community 🌍📚.

Publication Top Notes

📝 A Case of Treatment With a Combination of Covered Stents and Artificial Blood Vessel for Iliac Artery Rupture During Transcatheter Aortic Valve Replacement

📅 Year: 2025 | 📚 Journal: Clinical Case Reports

Efficacy and Safety of Different Dosing Regimens of Colchicine in Patients with Coronary Artery Disease: A Network Meta-analysis of 15 Randomized Controlled Trials

Effect of levocarnitine on TIMP-1, ICAM-1 expression of rats with coronary heart disease and its myocardial protection effect

Serum Amyloid a Promotes Visfatin Expression in Macrophages

Plumbagin mediates cardioprotection against myocardial ischemia/reperfusion injury through Nrf-2 signaling

Conclusion

Dr. Wang Shixun is a highly skilled and experienced medical professional in the field of Cardiovascular Medicine, currently serving as Deputy Director at Weifang People’s Hospital and applying for the position of Chief Physician. With a doctoral degree and nearly two decades of clinical service since 2006, he has consistently demonstrated excellence, as reflected in multiple years of outstanding evaluations. He also shows proficiency in foreign languages and computer applications. However, while his clinical credentials and leadership are commendable, there is currently limited evidence of significant research contributions—such as peer-reviewed publications, funded projects, or academic impact—needed to support a strong case for a Best Researcher Award.

Anna Truong | Cardiology | Best Researcher Award

Published on by Academic Awards

Ms. Anna Truong | Cardiology | Best Researcher Award

Pharmacist at Monash health, Australia

Anna Truong is a dedicated clinical pharmacist with extensive experience in cardiology, geriatrics, and intensive care 🫀💊. She holds a Master of Clinical Pharmacy and multiple postgraduate certificates from Monash University 🎓. Currently serving at the Victorian Heart Hospital, Anna actively contributes to patient care, clinical education, and multidisciplinary collaboration. Her roles have included research on medication titration for heart failure and involvement in the Virtual Hospital project. Known for her proactive and compassionate approach, she is committed to quality improvement and mentoring future pharmacists 🌟. Outside of work, she enjoys yoga, painting, and travelling 🧘‍♀️🎨✈️.

Publication Profile

Orcid

Academic Background

Anna Truong has a strong academic background in pharmacy and medicinal chemistry. She earned her Bachelor of Medicinal Chemistry, focusing on drug design and discovery, from Monash University Clayton/Parkville between 2006 and 2008 💊🔬. She then completed her Bachelor of Pharmacy with Honours at Monash University Parkville from 2009 to 2012. Further advancing her expertise, Anna attained graduate certificates in Geriatrics and Mental Health during 2015-2016 🧠👵. Most recently, she completed a Master of Clinical Pharmacy from Monash University Parkville between 2018 and 2020, solidifying her clinical knowledge and skills to excel in patient care and research.

Professional Experience

Anna Truong is a dedicated pharmacist with diverse clinical experience across multiple health settings. Since March 2023, she has worked as a rotational pharmacist at the Victorian Heart Hospital, actively participating in cardiology ward rounds and educating new pharmacists and students 🏥❤️. From 2019 to 2023, she served at Monash Health Clayton, covering cardiology, intensive care, neurosurgery, and surgical areas, contributing to clinical projects and mentoring students 🏨📋. Earlier roles include clinical pharmacist positions at Peninsula Health Frankston and Middlemore Hospital Auckland, where she supported geriatric and orthopaedic care, supervised pharmacy training, and enhanced medication safety 🧓🔬. Her early career included locum pharmacist and intern roles, providing patient-focused medication management across diverse clinical areas.

Awards and Honors

Anna Truong has been recognized for her dedication and excellence in clinical pharmacy. Throughout her career, she has received commendations for her leadership in cardiology pharmacy services and contributions to quality improvement projects 💊👏. Her commitment to education and mentorship has earned her appreciation from both colleagues and students 🎓🤝. Anna’s proactive approach in optimizing medication safety and patient care has been acknowledged in hospital award programs and pharmacy professional bodies 🏥🎖️. These honors reflect her passion for advancing pharmacy practice and delivering exceptional healthcare outcomes.

Research Focus

Anna Truong brings extensive clinical expertise across Cardiology, Intensive Care, Neurosurgery, Surgery, General Medicine, and Geriatrics. She is deeply motivated to continuously learn and contribute to educating pharmacists, students, and interns, fostering exceptional patient care, especially in Cardiology 🫀📚. With excellent interpersonal and teamwork skills, she thrives in multidisciplinary environments, building strong professional relationships and mentoring future pharmacy professionals 🤝👩‍⚕️. Anna approaches her work with reliability, energy, and a proactive mindset focused on quality improvement. She adapts swiftly to fast-paced settings and excels in time management and organization, ensuring deadlines and patient needs are met efficiently ⏱️⚡.

Publication Top Notes

The impact of a transition of care electronic medication titration plan on optimising the treatment of heart failure after hospital discharge 🫀💊
Year: 2025 | Contributors: Anna Truong, Adeline Roussety 📄✨

Conclusion

Anna Truong is an outstanding candidate for a “Best Researcher Award” due to her leadership in clinically impactful research on electronic medication titration for heart failure, strong collaboration with multidisciplinary teams at Monash Heart, and active involvement in innovative projects like the Virtual Hospital and atrial fibrillation chatbot. Her extensive clinical experience across Cardiology, ICU, Geriatrics, and General Medicine, combined with her contributions to guideline development, education, and mentoring, demonstrate a deep commitment to advancing pharmacy practice. Coupled with her active role in quality improvement committees and professional credentials, Anna exemplifies excellence in clinical research and evidence-based care implementation.

 

 

HASAN SARI | Cardiology | Best Researcher Award

Published on by Academic Awards

Dr. HASAN SARI | Cardiology | Best Researcher Award

Dr. HASAN SARI, Mut State Hospital, Turkey

Dr. Hasan Sarı (b. 01.12.1991, Manavgat/Antalya) is a specialist in Cardiology. With several published works in leading journals, Dr. Sarı has contributed extensively to the fields of cardiac tumors, syncope, and aortic aneurysms. Notable publications include studies on malignant fibrous histiocytoma, right atrial thrombosis, and coronary ectasia. He has also presented at international conferences, including the ACC Middle East & Eastern Mediterranean 2023 in Athens. Dr. Sarı completed an observership at the University of Minnesota Medical Center in 2023. He is actively engaged in advancing cardiology research. 📚💉❤️📈

 

Publication Profile

Orcid

Research Focus

Dr. Hasan Sarı’s research primarily focuses on cardiology with a special interest in coronary artery diseases, cardiac arrhythmias, vascular pathology, and predictive models for cardiovascular conditions. His work includes evaluating the relationship between coronary ectasia and trimethylamine N-oxide, as well as exploring CHA2DS2-VASc scores and left ventricular apical thrombosis in heart failure patients. His research contributes to advancing cardiac diagnostics, understanding heart failure, and identifying biomarkers for cardiovascular health. Dr. Sarı’s publications are crucial for clinical practice and prevention strategies in cardiology. 🫀🔬💉📊

 

Publication Top Notes 📚

  • “The Evaluation of the Relationship Between Coronary Ectasia and Trimethylamine N‐Oxide” – International Journal of Clinical Practice (2024) 📅📝
  • “Kalp Yetmezlikli Hastalarda CHA2DS2-VASc Skoru ve Sol Ventrikül Apikal Trombozu İlişkisi” – Online Türk Sağlık Bilimleri Dergisi (2022) 📅📝